$ News

Cidara Therapeutics (CDTX): Assessing Valuation After a 137% One-Month Surge

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer

Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?

Is Cidara Therapeutics Fairly Priced After Its 110% Surge and New Clinical Milestones?

Cidara Therapeutics, Inc. (CDTX) Q3 2025 Earnings Call Transcript

What Makes Cidara Therapeutics (CDTX) an Investment Bet?

Cidara Therapeutics to Participate in November Investor Conferences

Cidara Therapeutics (CDTX): Revisiting Valuation Following Strong 1-Year Shareholder Returns

Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025

Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025

Cidara Therapeutics: A Potential Blockbuster In Flu Prevention

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025

Morgan Stanley Initiates Cidara Therapeutics (CDTX) With a Buy

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025

Why Cidara Therapeutics (CDTX) Is Up 12.4% After Breakthrough Therapy Status for Novel Flu Drug CD388

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025

Why Cidara Therapeutics Stock Crushed It Today

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention

Sector Update: Health Care Stocks Advance Premarket Friday